Last reviewed · How we verify
Active ASA
Active ASA is an aspirin-based medication developed by Hamilton Health Sciences Corporation. It is primarily used for its anti-inflammatory, analgesic, and antipyretic properties. Despite its widespread use, it does not have an FDA-approved label, which may limit its market potential. The drug's mechanism of action involves inhibiting cyclooxygenase enzymes, reducing the production of prostaglandins. Common side effects include gastrointestinal issues, such as nausea and bleeding, with varying frequencies. The drug is not recommended for certain populations, such as those with aspirin sensitivity or bleeding disorders.
At a glance
| Generic name | Active ASA |
|---|---|
| Also known as | ASPIRIN, ENTROPHEN CHEWABLE |
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Nonsteroidal Anti-Inflammatory Drug (NSAID) |
| Target | Cyclooxygenase (COX) enzymes |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
Common side effects
Drug interactions
- Warfarin (increased risk of bleeding)
- Selective serotonin reuptake inhibitors (SSRIs) (increased risk of bleeding)
- Corticosteroids (increased risk of gastrointestinal ulcers)
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease (PHASE2, PHASE3)
- A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression (EARLY_PHASE1)
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- The Effect of BWSTT on Neuroendocrine Profile and Functional Recovery in Stroke Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active ASA CI brief — competitive landscape report
- Active ASA updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI